EDs have been a major focus of HIV testing efforts in the United States, prompted by the fact that more than 125 million ED visits occur annually, 10 EDs serve substantial numbers of underserved patients, 11 and they are a common site of missed opportunities for diagnosing HIV infection. 12 Although alignment of federal recommendations provides an important foundation for guiding HIV prevention practices and broad HIV testing initiatives have raised awareness, 13, 14 relatively little has been done to ensure translation of such practices into routine emergency medical care. 15, 16 It remains unclear which methods of HIV screening are most effective and efficient for use in both academic and community EDs. In fact, the majority of EDs nationally do not routinely screen for HIV infection, 15, 16 evidenced by the finding that only approximately 0.3% of all ED visits include HIV testing. 17, 18 Acute HIV infection, a nonspecific clinical mononucleosis-like syndrome that occurs approximately 1 to 6 weeks after infection, represents a highly infectious phase of disease due to its association with extremely high viral loads. 3 To help identify acute infections, in 2010 the Food and Drug Administration approved the first 4th-generation HIV assay, the Architect HIV Ag/Ab Combo (Abbott Laboratories, Abbott Park, IL); since that time, two other 4th-generation platforms, GS HIV Combo Ag/Ab EIA (Bio-Rad Laboratories, Hercules, CA) and the Alere Determine HIV-1/2 Ag/Ab Combo (Alere Inc, Waltham, MA) have been approved for use in clinical settings. These assays, which detect both HIV-1 and HIV-2 immunoglobulin M and immunoglobulin G antibodies and HIV-1 p24 antigen, offer improved sensitivities (over 3rd generation assays) for identification of acute HIV infection while maintaining high sensitivities for established HIV infection, thereby affording the opportunity to increase the total number of patients identified with HIV infection. The CDC recently endorsed use of 4th generation assays when coupled with a single assay to differentiate between HIV-1 and HIV-2 (eg, Multispot HIV-1/HIV-2 Rapid Test [Bio-Rad Laboratories]), while using nucleic acid testing (NAT) (ie, viral load) for confirmation, when necessary. 19 Notably, for the new testing algorithm, Western blot is no longer recommended for confirmatory HIV testing given its relatively low sensitivity during early stages of HIV infection.
In this volume of Annals, Geren et al 20 contribute substantially to our understanding of HIV screening in EDs by reporting programmatic results of nontargeted opt-out screening in a high-volume, urban ED. This study is unique in that it reports, for the first time in an ED setting, the use of fourth-generation HIV testing. During the approximately 30-month study period, 71,556 eligible patients presented to the ED, resulting in 27,952 HIV tests performed and 78 (0.3%) confirmed positive results. Eligibility included patients aged 18 through 64 years, without previous HIV diagnoses, altered mentation, being residents of psychiatric or correctional facilities, or victims of severe trauma. Additionally, patients were not tested for HIV infection if blood was not drawn (32% of those who consented for HIV testing) or, in a very limited number of cases, an order was not entered into their electronic medical record. The results from this implementation study parallel findings from other studies reporting nontargeted opt-out HIV screening in EDs (Table 1) , [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] including the need to perform a large number of HIV tests to identify a relatively small number of infected individuals (ie, about 350 tests per positive result), a prevalence ranging from 0.2% to 0.6%, and the majority of patients not completing testing because they opted out or were ineligible for testing due to the clinical circumstance (eg, severe illness or injury), or because of another practical issue (eg, lack of a blood draw). These limitations raise questions about the overall system-level effectiveness of performing nontargeted HIV screening in an ED, particularly when external resources for integrating this preventive service into practice become increasingly limited.
The most striking finding reported in their article, however, was the number of those identified with acute infections. Of the 78 patients with confirmed positive results, 18 (23%) were identified with acute HIV infection and would not have been identified had an earliergeneration assay been used (ie, testing for antibody only). These patients, most of whom were highly infectious because of extremely elevated viral loads, would have otherwise been told they were uninfected and unknowingly continued to engage in behaviors that contribute to viral transmission. Use of fourth-generation HIV testing thus may significantly mitigate transmission of HIV infection. Furthermore, given the high diagnostic accuracy and comparable costs of fourth-generation testing compared with third-generation testing (ie, approximately $10 per test), we firmly believe that this newer technology should be integrated into ED-based HIV testing programs, if at all possible.
It is difficult, however, to clearly resolve the relatively high proportion of acute HIV infections identified in the Maricopa ED, and it remains uncertain whether these results are generalizable or if they represent a largely untested population or even a microepidemic. Although acute HIV infections represented only 0.06% of all tests performed (ie, approximately 1,667 tests per acute infection identified), the proportion of acute infections among all confirmed diagnoses was remarkably high. 20 Recent programmatic findings from our institutions support the notion that acute infections are identifiable in EDs. However, the proportion of acute infections relative to all confirmed positive results was significantly lower (approximately 10%) than that reported by Geren et al 20 (Table 2 ). This latter prevalence is similar to what has been reported in other studies, including 5% in an ED in New Orleans. 19, 38, 39 Although diagnosing acute HIV infection is important, we should not lose track of how much work remains to solve larger issues related to ED-based HIV screening in general (eg, broader dissemination and implementation and patient selection strategies). Unfortunately, data from across the United States suggest that even when efforts to integrate nontargeted HIV screening are implemented in EDs, only approximately 25% of eligible ED patients actually complete testing (Table 1) . Likely contributing to this unsettling statistic is the finding from 2 recent studies that most individuals who opt out do so because they believe they are not at risk for HIV infection. 34, 40 In addition, a significant proportion of patients in these studies were still identified relatively late in their disease courses.
Given the reality of limited existing ED-based prevention resources, alternative screening approaches may be more appropriate, with a focused effort on at-risk subpopulations. 41 As the proportion of undiagnosed HIV infection declines nationally, in accordance with goals of the National HIV/AIDS Strategy, the utility of non-risk-based HIV screening will likely diminish, making more targeted strategies reasonable, practical, and likely cost-effective. 42 Though the results are complex and still controversial, recent preliminary work found that risk-based screening using an empirically developed clinical prediction instrument was more strongly associated with identification of newly diagnosed HIV-infected patients than nonrisk-based screening. 31 Further focused research is required, however. Of the 18 ED implementation studies published to date, few have directly compared nontargeted screening with alternative screening or testing methods (eg, targeted screening or diagnostic testing), and none have found nontargeted screening to be superior in terms of rates of identification of newly diagnosed HIV infection. 25, 32, 34 A large multicentered clinical trial is currently under way to help further the understanding of the comparative effectiveness of targeted and nontargeted screening strategies in EDs. 43 As with the diagnosis of any clinical condition, one must look to actually find it; this holds true for HIV infection and, in particular, acute HIV infection. Fourth-generation HIV testing will improve our ability to identify a small but important group of individuals who are highly infectious and who otherwise do not know about their infections. However, the broader issues of engaging EDs in HIV screening and determining which patients should be tested remain the more fundamental challenge. Table 1 Peer-reviewed studies to date (N=18) reporting effectiveness of nontargeted HIV screening in EDs since 2006, stratified by consent method. Table 2 Fourth-generation HIV testing, confirmed HIV prevalence, and acute HIV infection prevalence among 4 urban EDs. 
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